Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 4, 2012, Pages 356-363

  Gerotziafas, Grigoris T ^a,b   Zarifis, John ^c   Bandi, Anastasia ^d   Mossialos, Lambros ^d   Galea, Vasso ^a,b   Tsinopoulos, George ^d   Chaari, Mourad ^a,b   Baccouche, Hela ^a,b   Sassi, Mouna ^a,b   Elalamy, Ismail ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Papanikolaou Hospital   (Greece)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

aspirin; clopidogrel; coronary artery disease; high platelet reactivity; multiplate; percutaneous coronary intervention; resistance

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL;

ACCURACY; ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ASSAY; BLEEDING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ELECTRODE IMPEDANCE AGGREGOMETRY; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT RESPONSE; VEIN PUNCTURE;

ADULT; AGED; ASPIRIN; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACENTAL FUNCTION TESTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84863479697     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611429122     Document Type: Article

References (38)

1. Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA. American College of Chest Physicians Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):708S-775S. (Pubitemid 351892976)
2. ESC Committee for Practice Guidelines. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology. Eur Heart J. 2008;29(23):2909-2945.
3. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-e286. (Pubitemid 43879461)
4. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126-2130. (Pubitemid 40617065)
5. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol. 2009;103(3 suppl):27A-34A.
6. Braunwald E, Angiolillo D, Bates E, et al. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008;31(3 suppl 1):I21-I27. (Pubitemid 351442478)
7. Zimmermann N, Hohlfed T. Clinical implications of aspirin resistance. Thromb haemost. 2008;100(3):379-390.
8. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug eluting stents. J Am Coll Cardiol. 2008;52(9):734-739.
9. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24(11):1980-1987. (Pubitemid 39482419)
10. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003;91(9):1123-1125. (Pubitemid 36514934)
11. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246-251. (Pubitemid 40094733)
12. Dominick J, Angiolillo DJ, Fernandez-Ortiz A, et al. Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives. JACC. 2007;49(14):1505-1516. (Pubitemid 46517957)
13. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96(6):781-788. (Pubitemid 44883819)
14. Von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-1001 and Multiplate1. Hamostaseologie. 2007;27(3):155-160. (Pubitemid 350092649)
15. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53(10):849-856.
16. Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost. 2010;103(1):151-159.
17. Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets. 2009;20(1):7-11.
18. Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate1 whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets. 2007;18(3):199-206. (Pubitemid 46744118)
19. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost. 2010;103(4):841-848.
20. Seth A, Serruys PW, Lansky A, et al. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention. 2010;5(7):788-794.
21. Cavallero E, Biondi-Zoccai G, Mazzanti A, et al. Repeat adverse events long after percutaneous coronary revascularization in diabetics. Minerva Cardioangiol. 2010;58(1):23-34.
22. Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT, E-Five Investigators. Safety and effectiveness of the endeavor zotarolimus-eluting stent in real-world clinical practice 12-month data from the e-five registry. JACC Cardiovasc Interv. 2009;2(12):1227-1235.
23. TAXUS IV Investigators. Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents 5-year final results of the TAXUS IV clinical trial (TAXUS IVSR: treatment of De novo coronary disease using a single paclitaxel-eluting stent). JACC Cardiovasc Interv. 2009;2(12):1248-1259.
24. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome-fact and fiction. Thromb Haemost. 2011;106(2):191-202.
25. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49(6):657-666. (Pubitemid 46205039)
26. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101(4):714-719.
27. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52(19):1557-1563.
28. Gerotziafas GT, Depasse F, Busson J, et al. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J. 2005;3:16.
29. Chantarangkul V, Clerici M, Bressi C, Tripodi A. Standardisation of the endogenous thrombin potential measurement: how to minimise the effect of residual platelets in stored plasma. Br J Haematol. 2004;124(3):355-357. (Pubitemid 38167987)
30. Vanschoonbeek K, Feijge MA, Van Kampen RJ, et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost. 2004;2(3):476-284.
31. Konstantinidis K, Gerasimidis T, Verdy E, Elalamy I, Samama MM, Gerotziafas GT. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood. Thromb Haemost. 2007;97(1):109-118.
32. Elalamy I, Chakroun T, Gerotziafas GT, et al. Circulating platelet-leukocyte aggregates: a marker of microvascular injury in diabetic patients. Thromb Res. 2008;121(6):843-848. (Pubitemid 351506449)
33. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004;164(19):2106-2110. (Pubitemid 39410798)
34. Bouman H, Parlak E, van Werkum J, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost. 2010;8(3):482-488.
35. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008;28(3):S25-S32.
36. Price MJ, Agniolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention. A time-dependent analysis of the gauging responsiveness with VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation. 2011;124(10):1132-1137.
37. Kopp CW, Gremmel T, Steiner S, et al. Platelet-monocyte cross talk and tissue factor expression in stable angina vs unstable angina/non ST-elevation myocardial infarction. Platelets. 2011;22(7):530-536.
38. Gresele P, Falcinelli E, Loffredo F, et al. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role for sustained platelet activation. Eur Heart J. 2011;32(3):316-325.